The FDA approved minocycline hydrochloride extended-release capsules (Emrosi) for treating inflammatory lesions of rosacea in ...

Journey Medical has claimed FDA approval for its Emrosi therapy for rosacea, which it thinks could become a "standard of care" drug for the common skin disorder. The new capsule formulation of the ...

U.S. FDA approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults; launch expected in late Q1 or early Q2 of ...

Emrosi Approved to Treat Inflammatory Lesions of Rosacea Aucatzyl (obecabtagene autoleucel ... and dermatofibrosarcoma protuberans. FDA Approves Imatinib Oral Solution Imkeldi Revuforj (revumenib ...

Emrosi approved by FDA on November 4 for the treatment of inflammatory lesions of rosacea in adults Cosibelimab PDUFA goal date of December 28 for potential approval to treat metastatic or locally ...